Management of patients with inflammatory bowel disease during the covid-19 pandemic

2Citations
Citations of this article
28Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The pandemic caused by the SARS-Cov-2 virus originating in Wuhan, capital of the province of Hubei (China), has become a challenge for humanity. It is a highly contagious virus and up to now the COVID-19 disease has an overall mortality of around 6 %, which is higher in patients with comorbidities. Inflammatory bowel disease (IBD) is a disabling pathology, with tissue damage and impaired immune response, which, associated with immunosuppressive drugs that are frequently used for their treatment, put the patient at risk of developing infections and complications. In this review we consider the interaction of the SARS-CoV-2 virus with the gastrointestinal tract and the potential mechanisms whereby a patient with IBD could have an increased risk of COVID-19 infection. Additionally, and despite the fact that there are no published clinical studies in patients with IBD and COVID-19, we make recommendations based on the opinion of experts on the care of patients with IBD, with an emphasis on its treatment and the safe performance of endoscopic procedures, both for the patient and the health personnel.

Cite

CITATION STYLE

APA

Juliao-Baños, F. (2020, December 1). Management of patients with inflammatory bowel disease during the covid-19 pandemic. Revista Colombiana de Gastroenterologia. Asociacion Colombiana de Gastroenterologia. https://doi.org/10.22516/25007440.537

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free